MSC-Exos Promote Healing of MHs

Study Overview
=================
Brief Summary
-----------------
Purpose: To assess the safety and efficacy of mesenchymal stem cells (MSCs) and MSC-derived exosomes (MSC-Exos) for promoting healing of large and refractory macular holes (MHs). Hypothesis: MSC and MSC-Exo therapy may promote functional and anatomic recovery from MH. MSC-Exo therapy may be a useful and safe method for improving visual outcomes of surgery for refractory MHs.

Detailed Description
-----------------
Based on the purpose and hypothesis,the participants with large and longstanding idiopathic MHs underwent vitrectomy, internal limiting membrane peeling, MSC or MSC-Exo intravitreal injection, and heavy silicon oil, air, 20% SF6, or 14% C3F8 tamponade. MSCs were isolated from human umbilical cord, and MSC-Exos were isolated from supernatants of MSCs via sequential ultracentrifugation. At the time of study enrollment, as well as physical examinations, best-corrected visual acuity (BCVA) and intraocular pressure will be measured and fundoscopy be performed. All diagnoses of MH are going to confirmed via spectral-domain optical coherence tomography (OCT), and the minimum linear diameter (MLD) of each MH will be measured parallel to the retinal pigment epithelium.The participants are going to be followed up for at least 6 months via BCVA measurement, fundoscopy, OCT, and physical examinations.

Official Title
-----------------
Mesenchymal Stem Cells Derived Exosomes Promote Healing of Large and Refractory Macular Holes

Conditions
-----------------
Macular Holes

Intervention / Treatment
-----------------
* Biological: exosomes derived from mesenchymal stem cells (MSC-Exo)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1.Clinical diagnosis of idiopathic macular hole whose diameter is greater than 400 microns Exclusion Criteria: Only one functional eye In other clinical trials. Other diseases which can affect visual acuity, such as cataract, diabetic retinopathy, glaucoma, corneal diseases, etc. Eye had undergone vitrectomy or scleral buckling, cataract surgery, Nd:YAG laser less than one month ago. Contralateral eye has poor prognosis than the study eye. Idiopathic or autoimmune uveitis history. Aphakic eye Physical condition is poor that can not keep prone position. Secondary macular lesions The equivalent spherical diopter of the study eye before any refractive correction or cataract surgery, which is greater than 6.0d or above 26mm of the ocular axis of the study eye. Intraocular pressure is higher than 25mmHg Within ocular inflammation, such as eye blepharitis, scleritis, keratitis and conjunctivitis. Systemic condition is poor, such as the poor control of diabetes and hypertension, myocardial infarction, cerebrovascular accident, renal failure and so on,and the researchers assessed those who are unable to complete the trail.

Ages Eligible for Study
-----------------
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental group<br>Our intervention is to add treatment of exosomes derived from mesenchymal stem cells (MSC-Exo) after pars plana vitrectomy(PPV) and ILM peeling. | Biological: exosomes derived from mesenchymal stem cells (MSC-Exo)<br>* After air-liquid exchange, 50μg or 20μg MSC-Exo in 10μl PBS was dripped into vitreous cavity around MH, leaving 20% SF6 or air as tamponade .<br>|
| No Intervention: Control group<br>Control group that receives treatment of only pars plana vitrectomy(PPV) and ILM peeling. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Macular holes closure | Minimum linear diameter (MLD) of the hole measured by OCT | baseline to 24 weeks post-surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best corrected visual acuity(BCVA) | BCVA using a Landolt C acuity chart method | baseline to 24 weeks post-surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
macular hole (MH), exosomes, mesenchymal stem cells, pars plana vitrectomy